Policy for Device Software Functions and Mobile Medical Applications

On 28 September 2022 the FDA published the final guidance on the regulatory oversight to certain software for industry and FDA staff.

FDA is issuing this guidance to communicate how the Agency intends to apply its regulatory oversight to certain software, including device software functions and mobile medical applications (MMAs) intended for use on mobile platforms or on general-purpose computing platforms.

Read more online 
Copyright Widler & Schiemann AG 2022. All Rights Reserved. /